{"title":"处方甲状腺替代不影响强化减肥计划的结果","authors":"Gerald C. Dembrowski, Jessica W. Barnes","doi":"10.1249/TJX.0000000000000092","DOIUrl":null,"url":null,"abstract":"\n With the complex role of the thyroid in metabolism and conflicting evidence of weight gain or loss as a result of prescription thyroid hormone replacement (THR), it is important to understand how THR affects weight loss beyond the standard measures of body weight % and body mass index (BMI). We examined differences in body composition improvement in individuals taking and not taking THR over 60 d of an intensive weight loss program. The 20Lighter Program (T20LP), a doctor-supervised weight loss and metabolic health program, included 6 wk of patent-pending very low calorie meal plans and a 3-wk customized transition back to a normal dietary intake. Of 2200 participants completing T20LP by December 31, 2017, ~10% reported taking prescription THR. From initial baseline to 60 d, T20LP participants from both groups showed statistically significant and clinically meaningful reductions in body weight, BMI, % body fat, visceral fat, metabolic age, and increases in % body water. To our knowledge, our study is the first large-scale analysis comparing weight loss outcomes in participants who take THR and participants who do not. Our data show both groups do equally well with respect to % body weight lost, BMI reduction, body fat and visceral fat reduction, and improvement in tissue hydration, and we found no disadvantage in any physiologic or metabolic outcome in weight loss participants on THR. Weight loss participants requiring prescription THR are capable of achieving body composition and metabolic improvements on par with those who do not require prescription THR.","PeriodicalId":75243,"journal":{"name":"Translational journal of the American College of Sports Medicine","volume":" ","pages":""},"PeriodicalIF":1.1000,"publicationDate":"2019-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":"{\"title\":\"Prescription Thyroid Replacement Does Not Affect Outcomes in an Intensive Weight Reduction Program\",\"authors\":\"Gerald C. Dembrowski, Jessica W. Barnes\",\"doi\":\"10.1249/TJX.0000000000000092\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n With the complex role of the thyroid in metabolism and conflicting evidence of weight gain or loss as a result of prescription thyroid hormone replacement (THR), it is important to understand how THR affects weight loss beyond the standard measures of body weight % and body mass index (BMI). We examined differences in body composition improvement in individuals taking and not taking THR over 60 d of an intensive weight loss program. The 20Lighter Program (T20LP), a doctor-supervised weight loss and metabolic health program, included 6 wk of patent-pending very low calorie meal plans and a 3-wk customized transition back to a normal dietary intake. Of 2200 participants completing T20LP by December 31, 2017, ~10% reported taking prescription THR. From initial baseline to 60 d, T20LP participants from both groups showed statistically significant and clinically meaningful reductions in body weight, BMI, % body fat, visceral fat, metabolic age, and increases in % body water. To our knowledge, our study is the first large-scale analysis comparing weight loss outcomes in participants who take THR and participants who do not. Our data show both groups do equally well with respect to % body weight lost, BMI reduction, body fat and visceral fat reduction, and improvement in tissue hydration, and we found no disadvantage in any physiologic or metabolic outcome in weight loss participants on THR. Weight loss participants requiring prescription THR are capable of achieving body composition and metabolic improvements on par with those who do not require prescription THR.\",\"PeriodicalId\":75243,\"journal\":{\"name\":\"Translational journal of the American College of Sports Medicine\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2019-09-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Translational journal of the American College of Sports Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1249/TJX.0000000000000092\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"SPORT SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational journal of the American College of Sports Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1249/TJX.0000000000000092","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"SPORT SCIENCES","Score":null,"Total":0}
引用次数: 3
摘要
由于甲状腺在代谢中的复杂作用以及处方甲状腺激素替代(THR)导致体重增加或减少的相互矛盾的证据,了解THR如何影响体重减轻是很重要的,超出了体重百分比和体重指数(BMI)的标准测量。我们研究了在60天的强化减肥计划中,服用和不服用THR的个体在身体成分改善方面的差异。20Lighter Program (T20LP)是一项由医生监督的减肥和代谢健康计划,包括6周正在申请专利的极低卡路里饮食计划和3周的定制过渡到正常饮食摄入量。在截至2017年12月31日完成T20LP的2200名参与者中,约10%的人报告服用处方THR。从初始基线到60 d,两组T20LP参与者的体重、BMI、体脂百分比、内脏脂肪、代谢年龄和体水百分比均有统计学意义和临床意义的降低。据我们所知,我们的研究是第一个比较服用THR和不服用THR的参与者减肥结果的大规模分析。我们的数据显示,两组在体重减轻%、BMI降低、体脂和内脏脂肪减少以及组织水化改善方面都做得很好,而且我们发现,服用THR的减肥参与者在任何生理或代谢结果上都没有不利之处。需要处方THR的减肥参与者能够达到与不需要处方THR的人相同的身体成分和代谢改善。
Prescription Thyroid Replacement Does Not Affect Outcomes in an Intensive Weight Reduction Program
With the complex role of the thyroid in metabolism and conflicting evidence of weight gain or loss as a result of prescription thyroid hormone replacement (THR), it is important to understand how THR affects weight loss beyond the standard measures of body weight % and body mass index (BMI). We examined differences in body composition improvement in individuals taking and not taking THR over 60 d of an intensive weight loss program. The 20Lighter Program (T20LP), a doctor-supervised weight loss and metabolic health program, included 6 wk of patent-pending very low calorie meal plans and a 3-wk customized transition back to a normal dietary intake. Of 2200 participants completing T20LP by December 31, 2017, ~10% reported taking prescription THR. From initial baseline to 60 d, T20LP participants from both groups showed statistically significant and clinically meaningful reductions in body weight, BMI, % body fat, visceral fat, metabolic age, and increases in % body water. To our knowledge, our study is the first large-scale analysis comparing weight loss outcomes in participants who take THR and participants who do not. Our data show both groups do equally well with respect to % body weight lost, BMI reduction, body fat and visceral fat reduction, and improvement in tissue hydration, and we found no disadvantage in any physiologic or metabolic outcome in weight loss participants on THR. Weight loss participants requiring prescription THR are capable of achieving body composition and metabolic improvements on par with those who do not require prescription THR.